





HOME | SUBMIT | FAQ | BLOG | ALERTS / RSS | ABOUT

♣ Follow this preprint

Advanced Search

Covid-19 vaccine safety in pregnancy, a nested case-control study in births from April 2021 to March 2022, England

Anna A Mensah, Julia Stowe, Jennifer E Jardine, Freja C M Kirsebom, Tom Clare, Meaghan Kall, Helen Campbell, Jamie Lopez-Bernal, Nick Andrews Helen Campbell, Nick A

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should *not* be used to guide clinical practice.

	□ □ 0 ■ 30		
Abstract	Full Text	Info/History	Metrics
Preview PDF			

Abstract

Introduction Vaccine safety in pregnancy is always of paramount importance. Current evidence of COVID-19 vaccine safety in pregnancy has been reassuring with no association found with negative maternal and neonatal outcomes. However, very few safety studies are conducted on a national level and investigate dosage, timing of vaccination as well as vaccine manufacturer. To fill this knowledge gap, we conducted a population based COVID-19 vaccine safety evaluation in England, including timing of vaccination by trimester, dosage and vaccine manufacturer received in pregnancy.

Method A matched case control study nested in a retrospective cohort where adverse maternal and neonatal pregnancy outcomes were compared across several COVID-19 vaccine exposures using conditional multivariable logistic regression, adjusting for a range of demographic and health characteristics. Eligible participants were identified from the national maternity services dataset (MSDS) and records were linked to hospital admission, national COVID-19 vaccine and COVID-19 testing databases. Matching criteria differed by outcome but included participant's age and estimated week of conception.

Results 514,013 pregnant individuals aged between 18 and 50 years were identified during the study period (births from 16th of April 2021-31st March 2022). Receiving at least one dose of COVID-19 vaccine during pregnancy conferred lower odds of giving birth to a baby who was low birthweight (aOR=0.86, 95% CI: 0.79 – 0.93), preterm (aOR=0.89, 95% CI: 0.85 - 0.92) or who had an Apgar score less than 7 at five mins of age (aOR=0.89, 95% CI: 0.80 - 0.98). There was no association between vaccination in pregnancy and stillbirth (aOR=0.90, 95% CI: 0.76 - 1.07), neonatal death (aOR=1.27, 95% CI: 0.91 - 1.77) perinatal death (aOR=0.98, 95% CI: 0.83 - 1.16), and maternal venous thromboembolism in pregnancy (aOR=0.82, 95% CI: 0.43 - 1.56). The odds of maternal admission to intensive care unit were lower in vaccinated pregnant women (aOR=0.85, 95% CI: 0.76 - 0.95).

Conclusion COVID-19 vaccines are safe to use in pregnancy and they confer protection against SARS-CoV-2 infection which can lead to adverse outcomes for both the mother and the infant. Our findings generated important information to communicate to pregnant women and health professionals to support COVID-19 maternal vaccination programmes.

What is already known on this topic Current evidence shows that COVID-19 vaccines are safe to use in pregnancy. However, few studies investigate the timing of vaccination in pregnancy including the first trimester for late pregnancy outcomes. Most studies are geographically limited, and few are population based allowing inclusion of participants representative of the country's inhabitants.

What this study adds This is the first population-based study in England investigating COVID-19 vaccine safety in pregnancy. We used the national maternity services dataset and national English

health services data enabling inclusion of a huge numbers of participants across the country. As such, we were able to investigate relevant safety research questions such as the timing of vaccine administration in pregnancy by trimester and before pregnancy, the number of doses received and vaccine manufacturer.

How this study might affect research, practice or policy This national study adds to further existing evidence demonstrating that all COVID-19 vaccines are safe to use in pregnancy at any point in time and gives pregnant individuals confidence in the COVID-19 maternal vaccine programme. We demonstrated that receiving multiple doses of COVID-19 vaccine in pregnancy is not associated with adverse pregnancy outcomes and additionally it was reassuring that there was no evidence of an increased risk by vaccine type.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

There was no external funding for this study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Surveillance of COVID-19 testing and vaccination is undertaken under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 to collect confidential patient information (www.legislation.gov.uk/uksi/2002/1438/regulation/3/made) under Sections 3(i) (a) to (c), 3(i)(d) (i) and (ii) and 3(3). The study protocol was subject to an internal review by the UK Health Security Agency Research Ethics and Governance Group and was found to be fully compliant with all regulatory requirements. As no regulatory issues were identified, and ethical review is not a requirement for this type of work, it was decided that a full ethical review would not be necessary.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Copyright

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

▲ Back to top



COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Subject Area

Epidemiology

Tweet

Subject Areas

All Articles

Addiction Medicine

Allergy and Immunology

Anesthesia

Cardiovascular Medicine

Dentistry and Oral Medicine

Dermatology

Emergency Medicine

Endocrinology (including Diabetes Mellitus and Metabolic

Disease)

Epidemiology

Forensic Medicine

Gastroenterology

Genetic and Genomic Medicine

Geriatric Medicine

Health Economics

Health Informatics

Health Policy

Health Systems and Quality Improvement

Hematology

HIV/AIDS

Infectious Diseases (except HIV/AIDS)

Intensive Care and Critical Care Medicine

Medical Education

Medical Ethics

Nephrology

Neurology

Nursing

Nutrition

Obstetrics and Gynecology

Occupational and Environmental Health

Oncology

Ophthalmology

Orthopedics

Otolaryngology

Pain Medicine

Palliative Medicine

Pathology

Pediatrics

Pharmacology and Therapeutics

Primary Care Research

Psychiatry and Clinical Psychology

Public and Global Health

Radiology and Imaging

Rehabilitation Medicine and Physical Therapy

Respiratory Medicine

Rheumatology

Sexual and Reproductive Health

Sports Medicine

Surgery

Toxicology

Transplantation

Urology

Chan
Supported by Zuckerberg
Initiative ③